MHH-PREB-1

Cat.No.: CSC-C0407

Species: Homo sapiens (Human)

Source: Lymph Node

Morphology: round cells growing singly or in clusters in suspension

Culture Properties: suspension

Inquire for Price

Specification
Background
Scientific Data
Q & A
Customer Review

Cat.No.

CSC-C0407

Description

Established from the lymph node of a 5-year-old Caucasian boy with B cell lymphoblastic non-Hodgkin lymphoma at diagnosis in 1994

Species

Homo sapiens (Human)

Source

Lymph Node

Recommended Medium

90-92.5% RPMI-1640 + 7.5-10% h.i. FBS

Culture Properties

suspension

Morphology

round cells growing singly or in clusters in suspension

Karyotype

Human hyperdiploid karyotype with 12% polyploidy - 48<2n>XYY, +21, ?ins(2;2)(q21;p15p22), t(8;14)(q24;q32)

Disease

B-Cell Non-Hodgkin Lymphoma

Quality Control

Mycoplasma: contamination was eliminated with Baytril (enrofloxacin), then negative in DAPI, microbiological culture, RNA hybridization, PCR assays
Immunology: CD3 -, CD10 +, CD13 -, CD19 +, CD20 +, CD34 -, CD37 +, CD38 +, cyCD79a +, CD80 -, CD138 -, sm/c

Storage and Shipping

Frozen with 70% medium, 20% FBS, 10% DMSO at about 6 x 10^6 cells/ampoule; ship in dry ice; store in liquid nitrogen

Synonyms

MHHPREB1

Citation Guidance

If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

MHH-PREB-1 is a human precursor B-cell leukemia cell line derived from a patient with precursor B-cell acute lymphoblastic leukemia (pre-B ALL). This cell line provides a useful in vitro model for the study of molecular mechanisms of B-cell development, leukemogenesis and therapeutic response in hematologic malignancies. The MHH-PREB-1 cells display immunophenotypic features of precursor B lymphocytes, including expression of early B-cell markers associated with immature lymphoid differentiation. MHH-PREB-1 cells are widely used in leukemia research because of their stable growth properties and reproducible biological behavior, especially in studies on signal transduction, regulation of apoptosis, drug resistance, and activation of oncogenic pathways. The cell line has also been used to study chromosomal aberrations and gene expression profiles in the progression of acute lymphoblastic leukemia.

Furthermore, MHH-PREB-1 offers a valuable platform for testing novel anticancer agents, targeted therapeutics, and immunomodulatory approaches. The model is also often used by researchers studying cytokine signaling, chemotherapy sensitivity, and interactions between leukemic cells and the microenvironment. MHH-PREB-1 remains a well-characterized pre-B ALL model that contributes to both basic leukemia biology and translational hematology research, thereby supporting the improvement of therapeutic strategies for pediatric and adult ALL.

C15:0 Had Selective Inhibitory Activities Against Specific Human Cancer Cell Types, Especially B-Cell Lymphomas

Pentadecanoic acid (C15:0), a saturated fatty acid, displays anticancer action at high doses, although its physiological effects are still unknown. Venn-Watson et al. tested C15:0 at concentrations ranging from 1.5 nM to 50 µM on 94 human cancer cell lines. Data from the Hs 229.T cell line were omitted since this line was classed as a fibroblast line.

C15:0 inhibited 13 (13.8%) cell lines with EC₅₀ ≤ 50 µM (6-47 µM). Most susceptible lines were non-Hodgkin B-cell lymphomas (n=8; 61.5%) with fewer hepatocellular (n=2), breast (n=2) and lung (n=1) cancer lines impacted. The lymphoma cell lines DOHH-2, GA-10, MHH-PREB-1 and SU-DHL-4 demonstrated EC₅₀, IC₅₀ and GI₅₀ values ≤ 50 µM (Figure 1). In contrast, majority of the lung (25/26), breast (15/17), pancreatic (13/13) and liver (5/7) cancer cell lines were resistant (EC₅₀ > 50 µM). With 81 (86.2%) cell lines resistant to the drug.

Dose-response curves (1.5 nm to 50 µM) of human cancer cell lines (a) DOHH-2, (b) GA-10, (c) MHH-PREB-1, and (d) SU-DHL-4 in which C15:0 had the most robust inhibitory activities (defined as EC50, IC50, and GI50 ≤ 50 µM). — Fig. 1. Dose-response curves (1.5 nm to 50 µM) of human cancer cell lines (a) DOHH-2, (b) GA-10, (c) MHH-PREB-1, and (d) SU-DHL-4 in which C15:0 had the most robust inhibitory activities (defined as EC₅₀, IC₅₀, and GI₅₀ ≤ 50 µM) (Venn-Watson S, 2025).

Ask a Question

Write your own review

You May Also Need

CM-1448Y

SuperCult® RPMI 1640 Medium

INQUIRY

CS-001Y

PremSera® FBS

INQUIRY

WILL-1

Description: Established in 2007 from the bone marrow mononuclear cells of an 82-year-old Japanese man with diffuse large B-cell lymphoma in the leukemic phase

Cat#: CSC-C0633 INQUIRY

View Product

TALL-1

Description: Established from the bone marrow of a 28-year-old man who developed the terminal leukemic phase of lymphosarcoma in 1976

Cat#: CSC-C0530 INQUIRY

View Product

KG-1

Description: This cell line was derived from the bone marrow aspirate of a 59 year old male with erythroleukemia that became acute myelogenous leukaemia.The cells form colonies in soft-agar in the presence of ...

Cat#: CSC-C8220L INQUIRY

View Product

L-82

Description: Established from the pleural effusion of a 24-year-old woman with recurrent anaplastic large cell lymphoma (ALCL); cells were described to clonally derive from T-lineage lymphoid cells and to be ...

Cat#: CSC-C0600 INQUIRY

View Product

SUP-HD1

Description: Established from a 37-year-old man at second (refractory/terminal) relapse of Hodgkin lymphoma (nodular sclerosing -> lymphocyte depleted/stage IIISA -> stage IV) after both combined chemo- and ...

Cat#: CSC-C0579 INQUIRY

View Product

MHH-CALL-4

Description: Established from the peripheral blood of a 10-year-old Caucasian boy with acute lymphoblastic leukemia (pre B-ALL) at diagnosis in 1993

Cat#: CSC-C0396 INQUIRY

View Product

For research use only. Not for any other purpose.